ManRos Therapeutics (Roscoff) develops molecules for the treatment of serious diseases: cystic fibrosis, polycystic kidney disease and neurodegenerative diseases (Alzheimer’s disease and Down’s syndrome/Trisomy 21). Phosphorylation abnormalities are observed in these three pathologies: they share identical molecular targets and similar action mechanisms.
In collaboration with the cystic fibrosis skill resource centre of the Ildys of Roscoff foundation and the Brest CHRU, ManRos Therapeutics has developed a molecule, roscovitine, which could revolutionise the treatment of cystic fibrosis. The 3rd and last phase of the “Rosco-cf” clinical study is currently conducted to evaluate the adequate tolerance of the molecule and to test at different doses in the treatment of patients with the disease.
Laurent Meijer who discovered roscovitine, points out the four potential effects of the molecule on patients: “Partially correct the main genetic mutation responsible for cystic fibrosis, strengthen the bactericidal capacity of patients to help fight against chronic infections, act as an anti-inflammatory agent and have an analgesic effect vis-à-vis the chronic pain associated with cystic fibrosis”.
Thirteen hospitals, specialised in cystic fibrosis, are involved in this study. Twelve patients were recruited to follow the last part of the protocol. The results are expected for September. If they are positive they will change the destiny of ManRos Therapeutics. Cystic fibrosis affects nearly 70,000 people in Europe and North America, including 7,000 in France.
Source : Ouest France – 02/01/2018
Photo credit : Manros Therapeutics